Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 835 results for "gilead sciences"

Gilead Sciences' Future in 3 Simple Slides
Motley Fool

Gilead Sciences' Future in 3 Simple Slides

Thanks to the launch of the hepatitis C drug Sovaldi in December 2013, Gilead Sciences' (NASDAQ: GILD 1. Dominating HIV therapy While Gilead Sciences' hepatitis C drugs have gotten all the press in the past year, the backbone of its success ... Motley Fool, 23 hours ago
[x]  

78 images for gilead sciences

Med India, 5 days ago
American Banking News, 1 week ago
MedIndia, 1 week ago
NDTV Profit, 1 week ago
Irish Times, 1 week ago
Livemint.com, 1 week ago
Bidness Etc, 3 weeks ago
Pharmafocus, 5 days ago
Jutia Group, 2 weeks ago
Nasdaq, 22 hours ago
MedIndia

Gilead Sciences, Inc. Harvoni Gets Preferred Status From UnitedHealth Group (UNH)

US insurer, UnitedHealthGroup Inc. ( NYSE:UNH ) has decided to back Gilead Sciences, Inc.'s ( NASDAQ:GILD )Harvonias a preferred treatment option for hepatitis C. This gives Gilead a significant lead in the price war withAbbVieInc ( NYSE:ABBV ). ...
 Bidness Etc2 days ago UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment  Reuters UK3 days ago UnitedHealth Suggests Gilead's Harvoni as Preferred Hepatitis C Treatment  MedIndia2 days ago UPDATE 2-UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment  Reuters UK3 days ago
[x]  
Med India

Strides signs licensing agreement with Gilead to commercialize HIV drug

Strides Arcolab Limited has entered into a licensing agreement with Gilead Sciences, Inc., a biotechnology company, under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide, or TAF, both as ...
 Individual.com5 days ago Strides Arcolab Inks Deal With Gilead Sciences for HIV Drug  Med India1 week ago Drug for Treatment of AIDS Awaits FDA Approval  Med India1 week ago Strides Arcolab, Gilead Sciences agreement  Financial Express1 week ago
[x]  

Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.49%

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $104.87 to a high of $107.77. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $106.11 on volume of 10.3 million shares. ...
 Individual.com5 days ago Watch for Gilead Sciences to Potentially Pullback After Gaining 1.49% Yesterday  Individual.com5 days ago Gilead Sciences (GILD) Crosses Pivot Point Resistance at $102.04  Individual.com1 week ago SmarTrend Watching for Potential Pullback in Shares of Gilead Sciences After 3.05% Gain  TradingCharts.com1 week ago
[x]  

Gilead Sciences (GILD) Showing Resistance Near $106.58

MarketIntelligenceCenter.com's patented algorithms have selected a trade on Gilead Sciences Inc (http://www.marketintelligencecenter.com/symbol/GILD"GILD) that returns 8.70% in 50 days for an annualized return rate of 63%. This diagonal spread pairs ...
 Individual.com2 days ago Gilead Sciences (GILD) Showing Bullish Technicals With Support At $99.81  Individual.com1 day ago

MSF criticises Gilead for expanding voluntary licence pact with 8 Indian cos on sofosbuvir and ledipasvir

Gilead Sciences's decision to expand its existing voluntary licence agreement with eight Indian generic companies for sofosbuvir and ledipasvir to include its investigational compound GS-5816 has come in for severe criticism from the international ...
 PharmaBiz4 days ago MSF criticises Gilead's voluntary licence agreement with eight Indian generic companies  Manufacturing Chemist3 days ago

Gilead Sciences (GILD) Trading Near $109.48 Resistance Level

With bullish technical indicators and a 5 STARS (out of 5) strong buy ranking from Standard & PooraEUR(TM)s, Gilead Sciences Inc (http://www.marketintelligencecenter.com/symbol/GILD"GILD) could be an attractive play for investors according to ...
 Individual.com4 days ago
Livemint.com

Delhi high court sets aside order on Gilead Sciences' Sovaldi patent

The Delhi High Court set aside an order from Deputy Controller of Patents and Designs rejecting a patent on Gilead Sciences' hepatitis C therapy Sovaldi, livemint.com reported. India's patent office declined to issue a patent for the therapy on the ...
 FirstWord Pharma1 day ago Delhi HC sets aside order on Gilead's Sovaldi patent  Livemint.com1 day ago HC seeks Centre reply on Gilead plea for patent of Hep C drug  Business Standard1 week ago

PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary

Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new ...
 24Dunia5 days ago
[x]  

GILEAD SCIENCES : Morningstar Recognizes John Martin as 2014 CEO of the Year

Morningstar named John Martin of Gilead Sciences the recipient of its 2014 CEO of the Year award. "Each of our three nominees lead companies that have an Exemplary Stewardship Rating, the highest rating our equity analysts assign based on their ...
 4 Traders6 days ago Gilead Sciences, Inc.'s John Martin Is Morningstar CEO Of 2014  Bidness Etc1 week ago Investment Firm Names Gilead Sciences, Inc.'s CEO Of 2014  BioSpace1 week ago Morningstar Names John Martin of Gilead Sciences as its 2014 CEO of the Year  Vision Monday1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less